Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva snags new CEO from Lundbeck

by Ryan Cross
September 18, 2017 | A version of this story appeared in Volume 95, Issue 37

Schultz
[+]Enlarge
Credit: Lundbeck
A photo of Teva's new CEO, Kåre Schultz.
Credit: Lundbeck

The indebted generics giant Teva Pharmaceutical has ended a seven-month search for its fourth CEO in six years, nabbing Kåre Schultz from the same role at the neuroscience drug developer Lundbeck and quelling rumors that AstraZeneca’s CEO would take the job. Schultz will move to Teva’s headquarters in Israel, where he will likely face discussions about dividing the firm into two entities, one focused on generics and the other on new drug development. Lundbeck’s stock fell on the news, while Teva’s began rebounding after a 15-year low.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.